These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7791152)

  • 1. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis.
    Maksymowych WP; Avina-Zubieta A; Luong MH; Russell AS
    J Rheumatol; 1995 Apr; 22(4):625-9. PubMed ID: 7791152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis.
    Dubost JJ; Soubrier M; Ristori JM; Beaujon G; Oualid T; Bussière JL; Sauvezie B
    Rev Rhum Engl Ed; 1997 Dec; 64(12):789-93. PubMed ID: 9476267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
    Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM
    Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
    Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
    J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy.
    Maksymowych WP; Aviña-Zubieta A; Luong M; Russell AS
    Clin Exp Rheumatol; 1996; 14(6):657-60. PubMed ID: 8978962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis].
    Ishii O; Yamada H; Ohya S; Moriuchi E; Kase C; Ichikawa Y; Yamasaki K
    Ryumachi; 1997 Dec; 37(6):810-5. PubMed ID: 9492569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Florczak M; Ostanek L; Brzosko M; Brzosko I; Szklarz BG
    Scand J Rheumatol; 2005; 34(1):22-6. PubMed ID: 15903021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of individualized diet challenges consisting of allergenic foods on TNF-alpha and IL-1beta levels in patients with rheumatoid arthritis.
    Karatay S; Erdem T; Yildirim K; Melikoglu MA; Ugur M; Cakir E; Akcay F; Senel K
    Rheumatology (Oxford); 2004 Nov; 43(11):1429-33. PubMed ID: 15304675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.